

# Announcing a **NEW** indication for Somatuline® Autogel®

Somatuline Autogel is now indicated for the treatment of adult patients with carcinoid syndrome



- > Somatuline Autogel (lanreotide): The **first and only SSA** with both an indication to **treat carcinoid syndrome** and with an **antiproliferative indication in enteropancreatic neuroendocrine tumours (NETs) to delay progression**. The antiproliferative effect was investigated in a phase 3 placebo-controlled trial that demonstrated a PFS benefit in patients with stable disease over 12 to 24 weeks.<sup>1</sup>

## Somatuline Autogel Indications

### Antiproliferative use in enteropancreatic NETs

Somatuline Autogel is indicated for the treatment of enteropancreatic NETs in adult patients with grade 1 or a subset of grade 2 (equivalent to Ki67 <10%) unresectable, locally advanced or metastatic disease to delay progression.

The effectiveness of Somatuline Autogel is based on a phase 3 placebo-controlled trial that demonstrated a benefit in PFS in patients classified with stable disease by RECIST criteria (<20% growth) over 12 to 24 weeks. There was no evidence of an overall survival benefit. Data on hindgut tumours were limited.


AND

### Carcinoid syndrome

Somatuline Autogel is indicated for the treatment of adult patients with carcinoid syndrome; when used, Somatuline Autogel reduces the administration frequency of short-acting somatostatin analogue rescue therapy.

## SAFE 'N' SOUND™ technology: Somatuline Autogel prefilled device\*†

### Prefilled device



Designed for consistent full-dose delivery by deep SC injection



Ready to use (no reconstitution required)



Only excipients are water for injection and glacial acetic acid (for pH adjustment)



Somatuline Autogel is for immediate and single use following first opening<sup>1</sup>

### SAFE 'N' SOUND technology



Automatic safety system to help prevent needle stick injury after use

PFS=progression-free survival; RECIST=Response Evaluation Criteria in Solid Tumors; SC=subcutaneous; SSA=somatostatin analogue

\* Clinical significance is unknown.

† Please consult the Product Monograph for complete dosage and administration instructions.

# Ordering Information:

Somatuline Autogel can be ordered through IPSEN Customer Service (Accuristix) or Canadian Pharmaceutical Distribution Network (CPDN).



## Product Specifications

Product description	DIN	UPC	CPDN
Somatuline Autogel <b>120 mg</b> prefilled syringe	02283417	3582186000991	900991

### IPSEN Customer Service (Accuristix)

Tel: 866-332-2301

Fax: 905-568-1329

Email: csrlpsen@accuristix.com

### CPDN

East Region

Tel: 866-322-2736

Fax: 877-322-0286

Email: cpdnprogramhelp@lynden.com

West Region

Tel: 866-895-2736

Fax: 877-895-0286



### Clinical use not discussed elsewhere in this piece:

- Safety and effectiveness in children <18 years of age have not been established.

### Contraindications:

- Patients who are hypersensitive to somatostatin or related peptides
- Patients with complicated, untreated lithiasis of the bile ducts

### Most serious warnings and precautions:

- **Loss of blood glucose control (hypoglycemia in diabetic patients; hyperglycemia):** monitor blood glucose levels; adjust treatment of diabetic patients accordingly
- **Reduced gall bladder motility:** may lead to gallstone formation; ultrasonography is advised at start of treatment then periodically thereafter
- **Drug interaction with cyclosporin:** monitor for decreased blood levels of cyclosporin

### Other relevant warnings and precautions:

- Allergic reactions including anaphylaxis and angioedema
- May lead to decrease in heart rate
- Decreased thyroid function
- Sinus bradycardia in patients with existing cardiac disorders
- Reduced intestinal absorption of coadministered drugs
- Not studied in patients with enteropancreatic neuroendocrine tumours in the setting of hepatic impairment or severe renal impairment
- Safety not established in pregnant or nursing women
- Patients should exercise caution when driving and operating machinery
- Not studied in patients with carcinoid syndrome in the setting of hepatic or renal impairment

### For more information:

Consult the Product Monograph at <http://ipsen.ca/wp-content/uploads/2018/02/Somatuline-Product-Monograph.pdf> for important information relating to adverse reactions, drug interactions and dosing which have not been discussed in this piece.

The Product Monograph is also available by calling IPSEN Medical Information at 1-855-215-2288.

**Reference:** 1. Somatuline® Autogel® Product Monograph, February 1, 2018.

IPSEN is a trademark of IPSEN S.A.

IPSEN CARES is a registered trademark of IPSEN S.A.

SOMATULINE and AUTOGEL are registered trademarks of IPSEN Pharma S.A.S.

SAFE 'N' SOUND is a trademark of Nemera La Verpillière SAS

© 2018 IPSEN Biopharmaceuticals Canada Inc. All rights reserved.